NOT KNOWN FACTUAL STATEMENTS ABOUT MBL77

. intolerance). Ibrutinib is The present gold standard therapy for individuals with relapsed/refractory sickness, based on the results of various section I-III trials, 115–119 but this is also changing for 2 principal factors: (i) a growing proportion of clients at the moment receive ibrutinib as frontline therapy; and (ii) a few major contenders